Seminars in Oncology
Volume 35 , Pages S22-S30 , April 2008

Clinical Studies With Epothilones for the Treatment of Metastatic Breast Cancer

  • Linda T. Vahdat

      Affiliations

    • Corresponding Author InformationAddress correspondence to Linda T. Vahdat, MD, Iris Cantor Breast Center, Weill Cornell Medical College, 425 East 61st St, 8th Floor, New York, NY 20021

References 

  1. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Oncologist. 2001;6:133–146
  2. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006;580:2903–2909
  3. Fojo T, Menefee M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol. 2007;18(suppl 5):v3–v8
  4. Chou TC, Zhang XG, Balog A, et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A. 1998;95:9642–9647
  5. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429–1437
  6. Vahdat L: Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist (in press)
  7. Fornier MN. Ixabepilone, first in a new class of antineoplastic agents: The natural epothilones and their analogues. Clin Breast Cancer. 2007;7:757–763
  8. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist. 2007;12:271–280
  9. Aghajanian C, Burris HA, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007;25:1082–1088
  10. Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res. 2005;11:6233–6239
  11. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res. 2004;10:1289–1298
  12. Awada A, Bleiberg H, de Valeriola , et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol. 2001;20:108a;(abstr 427)
  13. Hao D, Hammond LA, deBono JS, et al. Continuous weekly administration of the epothilone-B derivative, BMS247,550 (NSC710428): A phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol. 2002;21:103a;(abstr 411)
  14. Burris HA, Awada A, Jones S, et al. Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. Proc Am Soc Clin Oncol. 2002;21:104a;(abstr 412)
  15. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003;21:1866–1873
  16. Plummer R, Molife R, Verrill M, et al. Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies. Proc Am Soc Clin Oncol. 2002;21:78b;(abstr 2125)
  17. Hensley ML, Dizon D, Derosa F, et al. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs. 2007;25:335–341
  18. Thomas E, Bunnell C, Vahdat L, et al. A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Breast Cancer Res Treat. 2003;82(suppl 1):S83;(abstr 350)
  19. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol. 2006;24:568s;(abstr 10511)
  20. Vahdat L, Bunnell C, Schwartzberg L, et al. Ixabepilone is effective in combination with capecitabine in ER, PR, HER-2 negative (triple negative) patients (pts) resistant to taxanes and anthracyclines: final results from a breast cancer exploratory program. Ann Oncol. 2006;17(suppl 9):ix74;(abstr 159P)
  21. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007;25:3421–3427
  22. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS- 247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726–2734
  23. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25:3399–3406
  24. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415–3420
  25. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–3414
  26. Buzdar A, Silverman P, Kaufman PA, et al. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: Updated results. Breast Cancer Res Treat. 2005;94(suppl 1):S69;(abstr 1087)
  27. Toppmeyer DL, Mackey J, Sessa C, et al. Safety and efficacy of patupilone in patients with advanced breast cancer: A phase IIa trial. Breast Cancer Res Treat. 2006;100(suppl 1):S73–S74(abstr 1107)
  28. Ixempra™ (ixabepilone) prescribing information. Princeton, NJ: Bristol-Myers Squibb Co; 2007;
  29. Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol. 2007;25:3389–3391
  30. Roché H, Perez EA, Llombart-Cussac A, et al. Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): Data from neoadjuvant and metastatic breast cancer (MBC) trials. Ann Oncol. 2006;17(suppl 9):ix97–ix98(abstr 256P)
  31. Lee JJ, Low JA, Croarkin E, et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol. 2006;24:2084–2091
  32. Fornier MN. Epothilones in breast cancer: Review of clinical experience. Ann Oncol. 2007;18(suppl 5):v16–v21
  33. Estévez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res. 2003;9:686–692
  34. Llombart Cussac A, Baselga J, Manikhas G, et al. Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol. 2005;23:25s;(abstr 586)
  35. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat. 2005;94(suppl 1):S31;(abstr 305)
  36. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–5217
  37. Epothilone (ixabepilone) plus capecitabine versus capecitabine alone in patients with advanced breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00082433(accessed September 21, 2007)
  38. Chou TC, Zhang XG, Harris CR, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A. 1998;95:15798–15802
  39. Piro LD, Rosen LS, Parson M, et al. KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol. 2003;22:135;(abstr 539)
  40. Spriggs DR, Dupont J, Pezzulli S, et al. KOS-862 (epothilone D): Phase I dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc Am Soc Clin Oncol. 2003;22:223;(abstr 894)
  41. Holen KD, Syed S, Hannah AL, et al. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Am Soc Clin Oncol. 2004;22:133s;(abstr 2024)
  42. Marshall JL, Ramalingam S, Hwang JJ, et al. Phase I and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (pts) with advanced solid tumors. J Clin Oncol. 2005;23:145s;(abstr 2041)
  43. Monk JP, Calero-Villalona M, Dupont J, et al. Phase I trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors. J Clin Oncol. 2005;23:147s;(abstr 2049)
  44. Cortes C, Climent MA, Gomez P, et al. A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies. J Clin Oncol. 2006;24:86s;(abstr 2028)
  45. A study of epothilone D in combination with Herceptin (trastuzumab) in patients with HER-2 positive advanced or metastatic breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00337649(accessed October 11, 2007)
  46. Calvert PM, O'Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 2001;20:108a;(abstr 429)
  47. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol. 2005;23:9120–9129
  48. Aisner J, Gore M, Rubin EH, et al. Two phase IB trials of EPO906 plus carboplatin in patients with advanced malignancies. Proc Am Soc Clin Oncol. 2003;22:143;(abstr 574)
  49. Forster M, Kaye S, Oza A, et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res. 2007;13:4178–4184
  50. Dumez H, Van Oosterom AT, Rothermel JD, et al. Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer. J Clin Oncol. 2004;22:150s;(abstr 2093)
  51. Rinehart JJ, Rothermel JD, Anderson J, et al. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer. J Clin Oncol. 2004;22:219s;(abstr 3100)
  52. Wojtowicz M, Rothermel JD, Anderson J, et al. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer. J Clin Oncol. 2004;22:412s;(abstr 4623)
  53. Schmid P, Kiewe P, Kuehnhardt D, et al. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol. 2005;23:147s;(abstr 2051)
  54. Mekhail T, Chung C, Holden S, et al. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol. 2003;22:129;(abstr 515)
  55. Sessa C, Perotti A, Llado A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol. 2007;18:1548–1553
  56. Stopeck A, Moulder S, Jones S, et al. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. J Clin Oncol. 2007;25:114s;(abstr 2571)
  57. Chuang E, Vahdat L, Caputo T, et al. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229. J Clin Oncol. 2007;25:114s;(abstr 2570)
  58. Trastuzumab and ixabepilone in treating women with HER2-positive metastatic breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00079326(accessed September 21, 2007)
  59. Trastuzumab, ixabepilone, and carboplatin in treating patients with HER2/neu-positive metastatic breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00077376(accessed September 21, 2007)
  60. A trial of 2 schedules of ixabepilone plus bevacizumab and paclitaxel plus bevacizumab for breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00370552(accessed October 12, 2007)
  61. This is a neoadjuvant study of AC followed by ixabepilone or paclitaxel in early stage breast cancer that is HER-2 negative and estrogen receptors negative. http://www.clinicaltrials.gov/ct/show/NCT00455533(accessed October 12, 2007)
  62. Epothilone B in treating patients with CNS metastases from breast cancer. http://www.clinicaltrials.gov/ct/show/NCT00450866(accessed October 12, 2007)
  63. ZK219477 in patients with breast cancer and brain metastases. http://www.clinicaltrials.gov/ct/show/NCT00496379(accessed October 12, 2007)
  64. Wu S, Chasalow S, Lee H, et al. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. J Clin Oncol. 2007;25:103s;(abstr 2525)

 Dr Vahdat has no relevant financial relationships with commercial interests to disclose.

PII: S0093-7754(08)00042-0

doi: 10.1053/j.seminoncol.2008.02.003

Seminars in Oncology
Volume 35 , Pages S22-S30 , April 2008

Article Tools